Multiple Sclerosis Therapies Market to reach $28.00 million by 2026, At CAGR of 2.5%
Pune, Maharashtra, India, February 24 2021 (Wiredrelease) Allied Analytics –:Increase in number of pipeline drugs, surge in patient population, and rise in number of patient assistance programs (PAPs) drive the global multiple sclerosis therapies market. However, unspecified etiology of the disease restrains the market growth. On the other hand, the introduction of disease-modifying drugs and usage of off-label drugs will create new opportunities in the coming years.
According to the report published by Allied Market Research, the global Multiple Sclerosis Therapies Market generated $22.99 million in 2018, and is estimated to reach $28.00 million by 2026, registering a CAGR of 2.5% from 2019 to 2026.
According to the National MS society’s National Medical Advisory Committee, the decisions regarding disease modifying therapies should be collaboratively taken between the person with MS and his healthcare provider during the COVID-19 pandemic.
On the basis of their expert advice the society recommends that people with MS should follow CDC guidelines along with additional information for people at risk for serious illness from COVID 19. People with MS should continue DMTs and discuss precise risks with their MS healthcare provider before stopping a DMT.
On the other hand, the pharmaceutical providers all over the world are tackling the situation in terms of production to meet essential requirements. Moreover, the medicinal and other requirement for therapies may witnessed either shortage or delay due to disruption in the supply chain.
Download Sample Report: https://www.alliedmarketresearch.com/request-sample/1438
The report offers a detailed segmentation of the global MS therapies market based on type, route of administration, and region.
Based on type, the immunosuppressants segment contributed to the largest share in 2018, accounting for nearly two-thirds of the total share, and is estimated to maintain its dominant position during the forecast period. Moreover, this segment is estimated to portray the highest CAGR of 2.8% from 2019 to 2026. The report also analyzes the immunomodulators segment.
Based on route of administration, the oral segment accounted for the largest share in 2018, holding nearly half of the total share, and is expected to maintain the largest share throughout the forecast period. Moreover, this segment is estimated to portray the highest CAGR of 2.8% from 2019 to 2026. The report also analyzes the Injectable, and Intravenous segment.
The oral segment to maintain its leadership position during the forecast period-
Based on route of administration, the oral segment contributed to the highest market share with more than two-fifths of the global multiple sclerosis therapies market share in 2018, and is estimated to maintain its leadership position during the forecast period. Furthermore, the segment is estimated to generate the fastest CAGR of 2.8% from 2019 to 2026. This is due to significant therapeutic advances in the new orally administered drugs approved for the MS treatment.
Leading market players-
Bristol-Myers Squibb Company
F. Hoffmann-La Roche Ltd.
Teva Pharmaceutical Industries Ltd.
For Purchase Enquiry at: https://www.alliedmarketresearch.com/purchase-enquiry/1438
North America to maintain its dominant by 2026-
Based on region, North America, accounted for the highest share based on revenue, holding for nearly two-fifths of the total share of the global multiple sclerosis therapies market in 2018, owing to rise in U.S. FDA approvals for medications used in the treatment of MS and improved healthcare system in this region. However, LAMEA is estimated to portray the fastest CAGR of 3.1% from 2019 to 2026, owing to the high prevalence of MS in the Middle East countries.
Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of “Market Research Reports” and “Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.
This content has been published by Allied Analytics company. The WiredRelease News Department was not involved in the creation of this content. For press release service enquiry, please reach us at firstname.lastname@example.org.